tandospirone

structure given in first source

Also Known As:

3a,4,7,7a-hexahydro-2-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-4,7-methano-1H-isoindole-1,3(2H)-dione; SM 3997; SM-3997; 4,7-Methano-1H-isoindole-1,3(2H)-dione, hexahydro-2-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-, (3aalpha,4beta,7beta,7aalpha)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)

Networked: 107 relevant articles (27 outcomes, 33 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - tandospirone: 107
  - Piperazines: 26
    - tandospirone: 107
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Isoindoles: 18
      - tandospirone: 107

Experts

1.	Sumiyoshi, Tomiki: 8 articles (02/2022 - 06/2006)
2.	Meltzer, H Y: 6 articles (01/2018 - 06/2000)
3.	Hamada, Takeshi: 5 articles (12/2010 - 04/2002)
4.	Takei, Asako: 5 articles (12/2010 - 04/2002)
5.	Uehara, Takashi: 4 articles (02/2022 - 06/2006)
6.	Tashiro, Kunio: 4 articles (12/2010 - 04/2002)
7.	Kurachi, Masayoshi: 3 articles (02/2022 - 06/2006)
8.	Higuchi, Yuko: 3 articles (10/2013 - 05/2007)
9.	Meltzer, Herbert Y: 3 articles (07/2013 - 05/2007)
10.	Yabe, Ichiro: 3 articles (01/2005 - 04/2002)

Related Diseases

1.	Schizophrenia (Dementia Praecox) 12/01/2010 - "Effect of tandospirone on mismatch negativity and cognitive performance in schizophrenia: a case report." 06/01/2000 - "Effect of adjunctive treatment with serotonin-1A agonist tandospirone on memory functions in schizophrenia." 11/24/2017 - "More impressively, the beneficial effect of tandospirone has been revealed on improvement of motor dysfunction of Parkinson's disease and cognitive deficits of schizophrenia either in monotherapy or in combination with other drugs. " 01/01/2018 - "Adjunctive buspirone and tandospirone failed to show efficacy for psychotic symptoms, but adjunctive buspirone may be associated with improvement in extrapyramidal symptoms and cognitive deficits in schizophrenia. " 01/01/2015 - "Previous pilot clinical studies have shown that the serotonin 5-HT1A receptor agonist tandospirone has beneficial effect on cognitive deficits associated with schizophrenia. "
2.	Dementia (Dementias) 03/01/2019 - "Dose-Dependent Efficacy of Tandospirone for an Oldest-Old Patient With Behavioral and Psychological Symptoms of Dementia." 04/01/2007 - "The aim of this study was to assess the efficacy and safety of tandospirone, a 5-HT1A partial agonist, for treatment of behavioural and psychological symptoms of dementia (BPSD). " 04/01/2007 - "A preliminary open-label study of 5-HT1A partial agonist tandospirone for behavioural and psychological symptoms associated with dementia." 06/01/2002 - "The findings in the present study may suggest that tandospirone is a useful and comparatively safe drug for depression symptoms in senile patients with dementia." 08/31/2021 - "The severity of dementia was assessed using the Clinical Dementia Rating (CDR) scale; as the main outcomes, the severity of BPSD was assessed using the Clinical Global Impressions-Severity scale (CGI-S) and Neuropsychiatric Inventory-12 (NPI-12) at baseline and 4 weeks after the maintenance dose of tandospirone was reached. "
3.	Irritable Bowel Syndrome (Syndrome, Irritable Bowel) 01/01/2022 - "Moreover, it is interesting that tandospirone has been found to relieve gastrointestinal symptoms in patients with refractory irritable bowel syndrome who also have psychological dysfunctions. " 01/01/2022 - "In this study, using a visceral hypersensitivity rat model induced by chronic water avoidance stress to mimic the symptoms of irritable bowel syndrome, we found that tandospirone relieved anxiety-like behavior and visceral hypersensitivity induced by stress. " 08/28/2014 - "To investigate the efficacy of tandospirone in patients with irritable bowel syndrome-diarrhea (IBS-D) and anxiety in a prospective, randomized, controlled study. " 08/28/2014 - "Efficacy of tandospirone in patients with irritable bowel syndrome-diarrhea and anxiety."
4.	Cognitive Dysfunction 01/01/2023 - "The current study aimed to assess the efficacy of tandospirone citrate in VaDep cases with mild cognitive impairment (VaDep-MCI) as well as the role of plasma monoamine neurotransmitters during the treatment. " 01/01/2023 - "Augmentation therapy with tandospirone citrate in vascular depression patients with mild cognitive impairment: A prospective randomized clinical trial." 01/01/2014 - "Tandospirone, a 5-HT1A partial agonist, ameliorates aberrant lactate production in the prefrontal cortex of rats exposed to blockade of N-methy-D-aspartate receptors; Toward the therapeutics of cognitive impairment of schizophrenia." 06/15/2013 - "These results suggest that blonansein and risperidone, atypical APDs which lack a direct action on 5-HT1A receptors require 5-HT1A receptor stimulation to reverse the subchronic PCP-induced NOR deficit and provide a support for clinical trial of blonanserin in combination with tandospirone to ameliorate cognitive impairment in schizophrenia and to have fewer side effects." 09/30/2019 - "We measured the levels of cognitive impairment using the Morris water maze test and protein kinase A activity in hippocampal neurons on presynaptic and postsynaptic serotonin 1A receptors to investigate the effect of dizocilpine-induced cognitive impairment associated with atypical antipsychotic drugs in rats treated by quetiapine alone or combined with WAY100635/tandospirone. "
5.	Dyskinesias (Dyskinesia) 02/01/2002 - "Diverse effect of tandospirone may be caused by its partial agonist activity on 5-HT1A receptors, or may indicate that other causes for the expression of dyskinesia exist apart from excessive rise in brain DA levels. " 02/01/2002 - "Twelve weeks after tandospirone treatment, duration of dyskinesia, subjective and objective severity of dyskinesia, and parkinsonian features were evaluated. " 02/01/2002 - "The present study demonstrated that tandospirone is effective in alleviating L-DOPA-induced dyskinesia in 50% of the patients. " 02/01/2002 - "Tandospirone(15-60 mg/day) was administered to 10 patients with L-DOPA-induced peak-dose dyskinesia. " 07/01/2003 - "Drugs with 5HT-(1A) agonistic activity, such as buspirone and tandospirone, have been reported to be effective in reducing l-dopa-induced dyskinesias. "

Related Drugs and Biologics

1.	Citric Acid (Citrate)
2.	Serotonin 5-HT1 Receptor Agonists
3.	Buspirone (Buspar)
4.	Levodopa (L Dopa)
5.	Anti-Anxiety Agents (Anxiolytics)
6.	Lactic Acid (Lactate)
7.	Escitalopram
8.	Neurotransmitter Agents (Neurotransmitter)
9.	Opioid Analgesics (Opioids)
10.	Paroxetine (Paxil)

Related Therapies and Procedures

1.	Therapeutics
2.	Tympanoplasty
3.	Premedication
4.	General Anesthesia
5.	Telescopes